Inspira Activates U.S. Based Consulting Firm to Execute Transformational Initiatives
Inspira Technologies (NASDAQ: IINN) has engaged a specialized U.S.-based consulting firm to accelerate its strategic initiatives and expansion plans. The consulting firm, which specializes in biotech and medtech companies, will focus on executing high-value strategic transactions and accelerating commercial growth.
This engagement follows several key developments, including major purchase orders, formation of strategic frameworks with government health authorities, and the clinical integration of Inspira's ART100 system in Tier-1 U.S. hospitals. CEO Dagi Ben-Noon emphasized that the partnership aims to facilitate high-impact actions beyond internal execution capabilities, with results expected in the near term.
Inspira Technologies (NASDAQ: IINN) ha incaricato una società di consulenza specializzata con sede negli Stati Uniti per accelerare le sue iniziative strategiche e i piani di espansione. Questa società, esperta in aziende biotecnologiche e medtech, si concentrerà sull'esecuzione di transazioni strategiche di alto valore e sull'accelerazione della crescita commerciale.
Questo incarico segue diversi sviluppi chiave, tra cui importanti ordini di acquisto, la definizione di framework strategici con le autorità sanitarie governative e l'integrazione clinica del sistema ART100 di Inspira negli ospedali Tier-1 degli Stati Uniti. Il CEO Dagi Ben-Noon ha sottolineato che la partnership mira a facilitare azioni ad alto impatto oltre le capacità di esecuzione interne, con risultati attesi a breve termine.
Inspira Technologies (NASDAQ: IINN) ha contratado a una firma de consultoría especializada con sede en Estados Unidos para acelerar sus iniciativas estratégicas y planes de expansión. La firma, que se especializa en empresas biotecnológicas y medtech, se enfocará en ejecutar transacciones estratégicas de alto valor y acelerar el crecimiento comercial.
Este compromiso sigue a varios desarrollos clave, incluyendo grandes órdenes de compra, la formación de marcos estratégicos con autoridades sanitarias gubernamentales y la integración clínica del sistema ART100 de Inspira en hospitales Tier-1 de EE. UU. El CEO Dagi Ben-Noon enfatizó que la asociación busca facilitar acciones de alto impacto más allá de las capacidades internas de ejecución, con resultados esperados a corto plazo.
Inspira Technologies (NASDAQ: IINN)는 미국에 기반을 둔 전문 컨설팅 회사를 고용하여 전략적 이니셔티브와 확장 계획을 가속화하고 있습니다. 이 컨설팅 회사는 바이오텍 및 메드테크 기업을 전문으로 하며, 고부가가치 전략 거래 실행과 상업적 성장 가속화에 집중할 예정입니다.
이번 계약은 주요 구매 주문, 정부 보건 당국과의 전략적 프레임워크 형성, 그리고 Inspira의 ART100 시스템이 미국 Tier-1 병원에 임상 통합되는 등 여러 주요 발전에 따른 것입니다. CEO 다기 벤-눈은 이 파트너십이 내부 실행 능력을 넘어서는 고임팩트 조치를 촉진하는 것을 목표로 하며, 가까운 시일 내에 결과가 기대된다고 강조했습니다.
Inspira Technologies (NASDAQ : IINN) a engagé une société de conseil spécialisée basée aux États-Unis pour accélérer ses initiatives stratégiques et ses plans d'expansion. Cette société, spécialisée dans les entreprises biotechnologiques et medtech, se concentrera sur la réalisation de transactions stratégiques à forte valeur ajoutée et sur l'accélération de la croissance commerciale.
Cette collaboration fait suite à plusieurs développements clés, notamment d'importantes commandes d'achat, la mise en place de cadres stratégiques avec les autorités sanitaires gouvernementales, et l'intégration clinique du système ART100 d'Inspira dans des hôpitaux Tier-1 aux États-Unis. Le PDG Dagi Ben-Noon a souligné que ce partenariat vise à faciliter des actions à fort impact au-delà des capacités d'exécution internes, avec des résultats attendus à court terme.
Inspira Technologies (NASDAQ: IINN) hat eine spezialisierte US-amerikanische Beratungsfirma beauftragt, um seine strategischen Initiativen und Expansionspläne zu beschleunigen. Die Beratungsfirma, die sich auf Biotech- und Medtech-Unternehmen spezialisiert hat, wird sich auf die Durchführung wertvoller strategischer Transaktionen und die Beschleunigung des kommerziellen Wachstums konzentrieren.
Dieser Auftrag folgt auf mehrere wichtige Entwicklungen, darunter große Bestellungen, die Bildung strategischer Rahmenwerke mit staatlichen Gesundheitsbehörden und die klinische Integration von Inspiras ART100-System in Tier-1-Krankenhäusern in den USA. CEO Dagi Ben-Noon betonte, dass die Partnerschaft darauf abzielt, wirkungsvolle Maßnahmen über die internen Umsetzungskapazitäten hinaus zu ermöglichen, mit Ergebnissen, die kurzfristig erwartet werden.
- Clinical integration of ART100 system achieved in Tier-1 U.S. hospitals
- Secured major purchase orders
- Established strategic frameworks with government health authorities
- None.
Insights
Inspira engages specialized consulting firm to capitalize on recent commercial momentum and accelerate strategic growth initiatives.
Inspira Technologies has made a strategic move by bringing in specialized consulting expertise at what appears to be a critical inflection point in the company's development. This engagement follows what the company describes as significant commercial progress, including major purchase orders, formation of strategic frameworks with government-linked health authorities, and clinical integration of their ART100 system in top-tier U.S. hospitals.
The consulting firm specializes in three key areas that align with Inspira's current needs: structuring high-value strategic transactions, accelerating commercial growth, and transforming enterprise value. This suggests Inspira is preparing for a potential step-change in its business trajectory rather than incremental growth.
CEO Dagi Ben-Noon's statement that the engagement will "fundamentally redefine the scale" of the company indicates management believes they've reached a point where specialized expertise is needed to fully capitalize on their current momentum. The reference to "targeted engagements with high-level stakeholders" points to potential strategic partnerships or commercial arrangements beyond what their internal team can execute independently.
Most notably, the announcement suggests concrete results from these initiatives may materialize in the "very near term" during the second half of 2025, indicating these aren't long-range planning exercises but rather acceleration of already-in-motion initiatives. The focus on "scalable configurations" to expand global footprint suggests the company is positioning for significantly broader market penetration of its life-support and diagnostic technologies.
RA'ANANA, Israel, July 31, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it has activated a leading consulting firm to accelerate high-impact execution across strategic expansion, partner engagement, and advanced structuring pathways already in motion.
The consulting firm is a specialized group that partners with biotech and medtech companies at critical inflection points. The firm's expertise lies in structuring and leading the execution of high-value strategic transactions, accelerating commercial growth, and transforming enterprise value.
The engagement follows a series of high-impact developments including major purchase orders, the formation of national-level strategic frameworks with government linked health authorities, and clinical integration of Inspira’s ART100 system in Tier-1 U.S. hospitals. Collectively, these achievements position Inspira to scale its commercial platform and deepen alignment across the broader medtech ecosystem.
“The current pace and scale of opportunities requires more than internal execution, it demands coordinated, high-impact action,” said Dagi Ben-Noon, CEO of Inspira Technologies. “We are already working closely with our consulting firm on several initiatives with significant upside. We expect results from this process to begin surfacing in the very near term, fundamentally redefining the scale of our company.”
The consulting firm is currently facilitating targeted engagements with high-level stakeholders and evaluating scalable configurations to accelerate Inspira’s global footprint. The objective is to unlock execution pathways that can reshape the Company’s global market position and catalyze new layers of value creation in the second half of 2025.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it engaged the consulting firm to accelerate high-impact execution of the Company’s strategic expansion, partner engagement, and advanced structuring pathways already in motion, the belief that its recent achievements position it to scale its commercial platform and deepen alignment across the broader medtech ecosystem, the belief that the current pace and scale of opportunities require coordinated, high-impact action, the expectation of results from this process to begin surfacing in the very near term, and the objective to unlock execution pathways that can reshape the Company’s global market position and catalyze new layers of value creation in the second half of 2025. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ
What strategic initiatives has Inspira Technologies (IINN) announced in July 2025?
What recent achievements has Inspira Technologies (IINN) reported?
What is the purpose of Inspira Technologies' new consulting partnership?
Where is Inspira Technologies' ART100 system being implemented?
